Commentary|Articles|November 19, 2026

The Oncology Trial Has Changed, Has IRB Oversight Kept Up?

Listen
0:00 / 0:00

Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.

“The evolution of oncology research has required sponsors, investigators, and clinical development organizations to continuously reassess their capabilities and adapt their operating models.”

When selecting a contract research organization (CRO) to support an oncology development program, sponsors routinely undertake a rigorous assessment of therapeutic expertise. We evaluate the experience of the proposed cross-functional study management team, examine its familiarity with the relevant disease indications, and assess its ability to manage the scientific and operational complexities inherent in oncology research.

We recognize that therapeutic expertise is fundamental to the successful execution of a clinical trial. It informs operational decisions, facilitates appropriate risk management, and enables development teams to anticipate challenges that may otherwise compromise study conduct.

Yet the same degree of scrutiny is not always applied to the selection of the institutional review board (IRB) responsible for the ethical review and continuing oversight of that research. This disparity warrants closer examination.

Over the course of my career in oncology clinical development, I have witnessed a substantial transformation in both the science underlying investigational cancer therapies and the clinical trials designed to evaluate them. Advances in molecular characterization, precision medicine, immuno-oncology, and increasingly sophisticated therapeutic modalities have fundamentally reshaped how oncology clinical trials are designed, operationalized, and conducted.

These advances have also introduced levels of protocol complexity that require increasingly specialized clinical and scientific expertise across virtually every aspect of trial execution.It is reasonable to question whether our expectations for IRB oversight have evolved accordingly.

The increasing scientific complexity of oncology research

Contemporary oncology protocols bear relatively little resemblance to many of the studies conducted earlier in my career.

Clinical development programs increasingly incorporate biomarker-driven patient selection, adaptive trial methodologies, multiple treatment cohorts, and complex investigational regimens. The evaluation of novel therapeutic mechanisms, particularly in heavily pretreated or molecularly defined patient populations, introduces clinical considerations that may be highly specific to a particular malignancy or treatment modality.

Moreover, oncology protocols are rarely static documents.Emerging efficacy and safety data may necessitate modifications to eligibility criteria, dosing regimens, treatment schedules, monitoring requirements, or cohort structures. In some cases, these modifications materially alter the risk profile of the study or the population for whom participation may be appropriate. Each substantive amendment therefore presents considerations that extend beyond administrative or procedural review.

For example, expanding eligibility criteria to include patients with impaired organ function may require careful consideration of the investigational agent's pharmacologic properties, anticipated toxicities, and the adequacy of proposed safety monitoring. Similarly, the introduction of a new treatment cohort or combination regimen may necessitate reassessment of the information communicated to prospective and currently enrolled participants. These determinations require an understanding of the scientific rationale underlying the protocol and the clinical implications of the proposed modifications.

IRBs are appropriately charged with evaluating whether risks to participants are minimized, whether anticipated risks are reasonable in relation to potential benefits and the knowledge expected to result, and whether informed consent adequately communicates the information necessary for an autonomous decision.

The application of these regulatory criteria to complex oncology research can be materially informed by relevant therapeutic expertise. As oncology development becomes increasingly specialized, the expertise required to evaluate its ethical implications must receive commensurate attention.

Therapeutic expertise must be substantive, not merely representational

Federal regulations appropriately recognize that IRB membership must encompass the professional competence and diversity of experience necessary to evaluate the research under review. They also permit IRBs to obtain consultation when specialized expertise is required.

These provisions establish an important foundation. However, regulatory compliance alone does not fully address the breadth and depth of therapeutic expertise necessary for the review of contemporary oncology research. The presence of an oncologist on an IRB membership roster does not necessarily establish expertise across the diverse malignancies, investigational modalities, and emerging scientific developments that characterize modern oncology trials. Clinical expertise in one disease indication or therapeutic approach does not inherently translate to proficiency in another. Equally important is whether the appropriate expertise is meaningfully incorporated into the review of each protocol. Sponsors should understand the extent to which individuals with relevant clinical experience participate in initial protocol review, the assessment of substantive amendments, and the consideration of emerging safety information. This distinction becomes particularly important when evaluating studies involving novel mechanisms of action, heterogeneous patient populations, or treatment regimens with highly specialized toxicity profiles.

An IRB may possess extensive experience in the ethical and regulatory dimensions of human subjects research while having more limited familiarity with the clinical characteristics of a particular malignancy or investigational therapy. That observation does not diminish the importance of regulatory expertise. Rather, it underscores the complementary nature of regulatory proficiency and therapeutic knowledge. Effective oversight requires both.

Informed consent requires an understanding of the oncology treatment landscape

The importance of therapeutic expertise becomes particularly evident in the evaluation of informed consent.

Patients considering enrollment in oncology trials frequently confront complex medical circumstances, including advanced disease, limited established treatment alternatives, and considerable uncertainty regarding prognosis. Many have undergone multiple prior lines of therapy. Others may be evaluating investigational treatment relatively early in their disease course, when established therapeutic options remain available.

These differences have significant implications for how potential risks, anticipated benefits, therapeutic alternatives, and the burdens of study participation should be communicated.The evaluation of informed consent therefore requires more than confirmation that prescribed regulatory elements have been included in the consent document.

For studies involving novel agents or combinations, reviewers must consider whether the characterization of potential toxicities accurately reflects available evidence and its limitations. Protocol-mandated biopsies, intensive pharmacokinetic assessments, extended monitoring requirements, and other research procedures may introduce burdens that warrant particular considerations.

Changes in the therapeutic landscape may also affect the information necessary for participants to make an informed decision regarding continued study participation. A reviewer with relevant oncology experience will be better positioned to identify circumstances in which the presentation of clinical risks, potential benefits, or treatment alternatives requires additional clarification within the consent form.

The objective is not to substitute the IRB's clinical judgment for that of the investigator or treating physician to the sponsor, but rather to fortify it. The objective is to ensure that the ethical evaluation of the research is informed by an appropriate understanding of the clinical context in which participation decisions are made.

A higher standard for IRB selection

Within oncology clinical development, therapeutic specialization has become an established consideration in the selection of investigators, medical monitors, clinical scientists, and CRO partners. The rationale is straightforward: the complexity of the research requires professionals who possess the knowledge and expertise necessary to maximize scientific and ethical integrity for patients.

IRB selection should reflect the same principle.

Sponsors should move beyond evaluating IRBs predominantly through administrative capabilities and standardized service metrics. The qualifications of the individuals conducting the review, the processes through which specialized clinical knowledge is incorporated, and the board's experience overseeing complex oncology research deserve greater emphasis.

The evolution of oncology research has required sponsors, investigators, and clinical development organizations to continuously reassess their capabilities and adapt their operating models. It is appropriate to expect a comparable evolution in the standards by which IRB oversight is evaluated.

Oncology expertise should no longer be regarded as an optional differentiator in IRB oversight. It should be a fundamental expectation of sponsors selecting an IRB to oversee their oncology research.

Tiffany Crowell, senior vice president of clinical operations, Acrivon Therapeutics


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.